Rosiglitazone in the management of older patients with type 2 diabetes mellitus

International Journal of Clinical Practice

Volumn 56, Issue 7, 2002, Pages 538-541

  Kreider, Margaret ^a   Heise, M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; ROSIGLITAZONE;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIABETES CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBINS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 0036735199     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Prevalence of undiagnosed non-insulin-dependent diabetes mellitus and impaired glucose tolerance in a cohort of older persons with hypertension
2. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
3. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk)
4. Aging, comorbidity, and reduced rates of drug treatment for diabetes mellitus
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
6. Management of diabetes in the elderly
7. Hypoglycemia: A major problem in the management of diabetes in the elderly
8. Drug-induced hypoglycemic coma in 102 diabetic patients
9. Diabetes mellitus in older persons
10. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled, double-blind trial
11. The synthesis of BRL 49653: A novel and potent antihyperglycaemic agent
12. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
13. Rosiglitazone monotherapy is effective in patients with type 2 diabetes
14. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized, controlled, double-blind trial
15. Rosiglitazone short term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes
16. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
17. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in type 2 diabetic patients
18. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study
19. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
20. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after one year of treatment in type 2 diabetic patients
21. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus
22. Thiazolidinediones: A new class of antidiabetic drugs
23. Troglitazone has no effect on red cell mass or other erythropoietic parameters
24. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients
25. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat
26. Rosiglitazone (RSG; Avandia) pharmacokinetics are unaffected by renal impairment
27. Pharmacokinetics of rosiglitazone are unaltered in hemodialysis patients
28. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone